Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01371643 · OUTCOME

Percentage of Responders (Only Including Surgical Failures in Arm 2)

Surgical Debulking of Pituitary Adenomas · Source last updated 2016-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
3 months

What was measured

Nadir growth hormone \<1 ng/mL during a standard 2 hour oral glucose tolerance test using 75 g glucose and normal IGF-I according to age and gender-matched standards.

Groups in this outcome

Medical Treatment by Octreotide LAR

Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery Octreotide LAR

Surgical Debulking Followed by Octreotide LAR

Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured Octreotide LAR transsphenoidal surgery

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Medical Treatment by Octreotide LAR15
Surgical Debulking Followed by Octreotide LAR13

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Medical Treatment by Octreotide LAR6.7Not reported.231.9Not reported
Surgical Debulking Followed by Octreotide LAR53.9Not reported25.180.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        .2
        upper Limit
        31.9
        value
        6.7
      2. group Id
        OG001
        lower Limit
        25.1
        upper Limit
        80.8
        value
        53.9
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    2. group Id
      OG001
      value
      13
    units
    Participants
description
Nadir growth hormone \<1 ng/mL during a standard 2 hour oral glucose tolerance test using 75 g glucose and normal IGF-I according to age and gender-matched standards.
dispersion Type
95% Confidence Interval
groups
  1. description
    Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery Octreotide LAR
    id
    OG000
    title
    Medical Treatment by Octreotide LAR
  2. description
    Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured Octreotide LAR transsphenoidal surgery
    id
    OG001
    title
    Surgical Debulking Followed by Octreotide LAR
param Type
NUMBER
reporting Status
POSTED
time Frame
3 months
title
Percentage of Responders (Only Including Surgical Failures in Arm 2)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice